An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma.

Trial Profile

An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2016 Planned End Date changed from 1 Oct 2011 to 1 May 2022.
    • 06 Dec 2010 Preliminary results will be reported at ASH 2010.
    • 06 Dec 2010 According to a Roche media release, full study results will be presented in an abstract at the 52nd American Society of Hematology (ASH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top